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A pandemic (H1N1) 2009 virus strain carrying the 
D222G mutation was identiﬁ  ed in a severely ill man and 
was transmitted to a household contact. Only mild illness 
developed in the contact, despite his obesity and diabetes. 
The isolated virus reacted fully with an antiserum against 
the pandemic vaccine strain. 
O
n November 20, 2009, the Norwegian Institute of Pub-
lic Health reported to the World Health Organization 
a mutation in the hemagglutinin (HA) of pandemic (H1N1) 
2009 virus, consisting in a change of aspartic acid (D) with 
glycine (G) at aa 222. The mutation had been detected in 
3 patients (the ﬁ  rst 2 fatal cases in the country and in 1 
patient with severe pneumonia) among ≈70 other patients 
with pandemic (H1N1) 2009, suggesting that it was not 
widespread in Norway (1). The same mutation has been 
also detected in Brazil, China, Japan, Mexico, Ukraine, the 
United States, France, and Spain (1,2).
The D-to-G mutation among the 1918 inﬂ  uenza virus 
variants (3) correlated with a shift from α2-6–linked sialic 
acid preference to a dual α2-3/α2-6 speciﬁ  city. However, 
whether such a mutation may alter receptor binding speci-
ﬁ  city in the pandemic (H1N1) 2009 virus is unknown. 
Although several pandemic (H1N1) 2009 viral strains 
sharing this mutation were detected in fatal cases, the same 
mutation also was detected in some mild cases; conversely, 
viruses from numerous fatal cases have not shown the same 
mutation. Thus, the clinical and public health signiﬁ  cance 
of this ﬁ  nding remains unclear. The mutation appears to oc-
cur sporadically and spontaneously. No links between the 
small number of patients infected with the mutated virus 
have been found, and the mutation did not appear to spread 
(4). On the basis of results from a retrospective HA1 se-
quence analysis performed on pandemic (H1N1) 2009 viral 
isolates in Italy, we report on a transmission event of this 
virus carrying the D222G mutation. 
The Study
We reexamined the HA sequences of 130 inﬂ  uenza A 
(H1N1) virus strains identiﬁ  ed from patients affected by 
pandemic (H1N1) 2009. The neuraminidase sequences of 
some of these viruses also have been analyzed. 
All 130 strains had been obtained from clinical samples 
(nasal, pharyngeal, or nasopharyngeal swabs and/or trache-
al aspirates) collected during May–November 2009 in the 
context of virologic surveillance conducted by the National 
Inﬂ  uenza Centre, in collaboration with the regional labora-
tory network. These samples were obtained aimed to study 
the evolution of the pandemic strain. Forty-one HA gene se-
quences examined in the present study were retrieved from 
the National Center for Biotechnology Information, 3 from 
the Global Initiative on Sharing Avian Inﬂ  uenza Data da-
tabase, and 86 HA sequences (47 directly from the clinical 
samples and 39 from cell culture supernatant) were obtained 
at the National Inﬂ  uenza Centre (NIC) with the following 
procedure. Viral RNAs were extracted by using the QIAamp 
Viral RNA Mini Kit (QIAGEN, Santa Clara, CA, USA) 
and ampliﬁ  ed by reverse transcription–PCR (RT–PCR) (5). 
HA amplicons were sequenced by using the BigDye Ter-
minator Cycle-Sequencing Ready Reaction (Applied Bio-
systems, Foster City, CA, USA) and ABI Prism 310 DNA 
sequencer (Applied Biosystems). All the NIC sequences 
were deposited in the GenBank database under the acces-
sion numbers reported in the Figure. Sequences were as-
sembled and aligned using Lasergene package, version 4.0 
(DNASTAR, Madison, WI, USA). BioEdit software ver-
sion 4.0 (www.mbio.ncsu.edu/BioEdit/bioedit.html) of the 
MEGA software package (www.megasoftware.net) was 
used to estimate phylogenies from the nucleotide sequences 
and to construct phylogenetic trees by using the neighbor-
joining algorithm and maximum-likelihood method. 
Among 130 patients, 23 of whom had severe disease 
(i.e., requiring hospitalization), only 1 was infected with a 
virus showing the D222G change. The patient, a man 25 
years of age from northern Italy, had a febrile illness on 
August 17. One week later, he was admitted to an inten-
sive care unit with severe pneumonia and acute respiratory 
distress syndrome, which resolved after treatment with 
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viral genome showing the D222G mutation was identiﬁ  ed 
through direct sequencing of nasopharyngeal swab and tra-
cheal aspirate collected on August 27. No sequence could 
be retrieved from a nasal wash, which was obtained the 
same day and was positive in real-time RT–PCR for pan-
demic (H1N1) 2009 virus. No viral growth was detected in 
MDCK cells seeded with both clinical samples.
To identify possible transmission chains of the mutated 
virus, we analyzed the genome of the viral strain detected 
in the throat swab of the father of the index case-patient, 55 
years of age, who was obese and had diabetes. He became 
moderately ill on August 25 but did not require hospital-
ization or antiviral treatment. The virus isolated in MDCK 
cells from the sample obtained on August 27 had the same 
HA mutation, D222G. Viral strains from index and contact 
cases were susceptible to oseltamivir, as determined by lack 
of the speciﬁ  c oseltamivir-resistance marker (His274Tyr, 
N2 numbering) in neuraminidase sequences, which were 
identical in both viral strains. Additional samples analyzed 
from close contacts (i.e., 4 healthcare workers, 4 family 
members, and 2 friends) of the 2 patients all were negative 
for pandemic (H1N1) 2009 virus.
Comparison of the 2 HA1 sequences from the index 
case-patient and his father showed an additional substitu-
tion in the latter (G155E), which is located close to the 
receptor-binding pocket. Furthermore, sequence analyses 
showed that all virus strains containing a change in HA1 
position 222 (D222G or D222E) also showed a second sub-
stitution in position 203 (D203T), when compared with the 
A/California/7/2009 vaccine strain (Figure). However, the 
effect of this second mutation on the HA receptor-binding 
properties is still unclear. The HA1 genes from the index 
and contact case-patients shared 2 additional nucleotide 
changes, 1 synonymous substitution (T504C, N1 number-
ing) not found in any other sequence analyzed in the present 
study and another nucleotide change resulting in an amino 
acid substitution (P297S, N1 numbering), detected only in 
a small number of sequences from Italy. Hemagglutination-
inhibition test of the isolated virus did not show substantial 
reduction in its reactivity with an antiserum against pan-
demic (H1N1) 2009 vaccine, as compared with the reac-
tivity of an inﬂ  uenza virus A/California/7/2009 strain not 
carrying the G155E mutation (Table). 
Conclusions
Identiﬁ  cation of a pandemic (H1N1) 2009 virus strain 
carrying the D222G mutation and its association with the 
ﬁ  rst fatal cases of inﬂ  uenza in Norway raised some concern 
about emergence of a viral strain with increased pathoge-
nicity. No data have been reported on transmission capacity 
of this and other D222G variants, occasionally identiﬁ  ed 
worldwide. Our ﬁ  ndings suggest that the D222G mutated 
virus is to some extent transmissible. However, a number 
of close contacts were identiﬁ  ed who did not acquire the 
infection.
Whether the mutated virus may have a lower ﬁ  tness 
for receptors in the high respiratory tract, which may affect 
transmission, remains undeﬁ  ned. Furthermore, the muta-
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Figure. Phylogenetic relationships of hemagglutinin (HA) 1 
sequences of pandemic (H1N1) 2009 viruses in Italy obtained from 
the National Inﬂ   uenza Centre (NIC)–Istituto Superiore di Sanità 
(ISS) and the National Center for Biotechnology Information. 
The NIC-ISS sequences are in italics. Isolates from the index 
case-patient and his father are indicated in boldface. Amino acid 
mutations of interest in this study are reported on the nodes. All 
the NIC sequences obtained in the present study were deposited 
in the GenBank database under the following accession numbers: 
(hemagglutinin sequences) GU451262–GU451280; GU576500–
GU576502; GU576504; GU576506; GU576508; GU576510; 
GU576512; GU576514-GU57615; GU576517; GU576519; 
GU576521-GU576522; GU576524; GU576526-GU576527; 
GU576529; GU576531-GU576532; GU576534; GU576536-
GU576540; GU585403–GU585443; (neuraminidase sequences) 
GU936490-GU936491. Scale bar indicates proportion of nucleotide 
substitutions per site.Mutant Strain of Pandemic (H1N1) 2009 Virus 
tion, which was ﬁ  rst found in a severely affected man, was 
transmitted to a family member (father), who had only a 
mild illness, despite risk for severe infection. The HA1 se-
quence from this latter case presented an additional amino 
acid substitution (G155E), which was not found in any 
other sequence analyzed in our study and rarely detected 
among all sequences available from GenBank. Recent data 
suggest that amino acid substitution at this position may be 
critical for the switch from dual α2-3/α2-6 binding speciﬁ  c-
ity to α2-6 linkage (6), which is preferentially recognized 
by human inﬂ  uenza viruses and expressed mainly in the 
upper respiratory tract. This change might be partially re-
sponsible for the milder inﬂ  uenza illness developed by the 
father of the index case-patient. In addition, the G155E mu-
tation in laboratory-generated variants of pandemic (H1N1) 
2009 virus has been associated with loss of antigenicity (7). 
In our study, the natural isolates of the virus carrying both 
the G155E and the D222G mutations had comparable anti-
genicity with the A/California/7/09-vaccine strain. Finally, 
our data do not support the association of the D222G muta-
tion with severe disease. 
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Table. Hemagglutination-inhibition test results of pandemic (H1N1) 2009 viruses, Italy 
Viruses 
Postinfection ferret serum titer against 
A/Brisbane/59/2007 seasonal H1N1  A/California/7/2009 pandemic H1N1 
A/Brisbane/59/2007 (H1N1) 1,280  <10
A/California/7/2009 (H1N1v) <10 1,280 
Father’s virus isolate (D222G + G155E) <10 640
A/Rome/ISS11/2009 <10 320